Cochlear (OTCMKTS:CHEOF) & Ainos (OTCMKTS:AIMD) Head-To-Head Contrast

Cochlear (OTCMKTS:CHEOF) and Ainos (OTCMKTS:AIMD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk and institutional ownership.

Insider and Institutional Ownership

22.5% of Cochlear shares are held by institutional investors. Comparatively, 0.3% of Ainos shares are held by institutional investors. 4.6% of Ainos shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Cochlear and Ainos’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cochlear	N/A	N/A	N/A
Ainos	-515.80%	-44.32%	-40.35%

Earnings and Valuation

This table compares Cochlear and Ainos’ revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cochlear	N/A	N/A	N/A	$1.64	143.03
Ainos	$93,677.00	47.01	-$14.01 million	($2.55)	-0.27

Cochlear has higher earnings, but lower revenue than Ainos. Ainos is trading at a lower price-to-earnings ratio than Cochlear, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Cochlear and Ainos, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cochlear	0	0	0	0	N/A
Ainos	0	0	0	0	N/A

Summary

Cochlear beats Ainos on 6 of the 8 factors compared between the two stocks.

About Cochlear

Cochlear Limited provides implantable hearing solutions for children and adults worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.

About Ainos

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.